OR-AIRSHIP
29.10.2020 09:32:07 CET | Business Wire | Press release
Customer engagement company Airship today detailed the amazing success three brand marketers have achieved using Airship Journeys to more quickly and easily improve the business impact of cross-channel customer journeys. The customer journeys these marketers have optimized have driven double- and even triple-digit percentage performance improvements over baselines established by control groups.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005340/en/
Airship Journeys combines everything marketers need to create, evaluate, test and optimize cross-channel customer engagement journeys in a single, intuitive visual UI. Only Airship Journeys allows marketers to zoom in from glanceable, color-coded visualizations of journey performance against business goals and baselines, to view and optimize any underlying message with A/B testing.
As the largest professional social network and digital distribution platform for musicians and other creative types, Vampr has created numerous journeys since selecting Airship in August 2020. A recently launched reactivation journey targets app users who have been inactive for five days with a series of three push notifications and a final email within two weeks, and has been found to reactivate users at a 277 percent higher rate than those in the control group.
“My goal is to drive critical business KPIs by getting users to complete their profiles, connect with nearby creatives, add their original songs and videos, and much more — 90 percent of the time I’m using Airship Journeys to optimize these user experiences,” said Jessy Trengove, head of insights, Vampr. “By being able to easily see journey performance against baseline metrics and control groups, I’m more easily able to achieve the goals that make a real difference to the business.”
On Black Friday, J. C. Penney Company, Inc. used Airship Journeys to transform a one-message cart abandonment automation into a two-message journey and found significant lift in completed purchases. This cart abandonment journey now shows an all-time increase of 40 percent higher purchase completion rates over the control group baseline. JCP reactivation messages spread across three separate automations are now being combined into a single journey, enabling a goal-based view of business impact rather than trying to draw conclusions by comparing each message’s engagement metrics.
“With Airship Journeys, we can see where each customer comes into and progresses through each phase and can more easily A/B test any message in the journey to optimize timing, triggers, copy and content,” said Haley Welmon, owned media specialist, JCPenney. “Airship Journeys control groups and baselines help us make decisions and increase revenue more quickly, so we can maximize our success and ensure that what we think is the best experience for the customer, actually is.”
In hospitality, in their mobile app, Radisson Hotel Group has created a cart abandonment journey series spanning three messages over four days — the first of which guarantees the room’s rate — driving an 11 percent lift in completed reservations over the control group.
Tune in to the webinar, “Creating Extraordinary Customer Journeys with a Culture of Experimentation,” live Thursday, October 29 at 10am PDT / 1pm EDT / 5pm GMT / 6pm CET (recording available to registrants), and learn how to gain advantage by experimenting, testing and optimizing critical cross-channel customer journeys.
“It’s so gratifying to see how quickly brands have realized substantial business gains due to the powerful way we’ve reinvented cross-channel journeys for the mobile era,” said Brett Caine, CEO and president, Airship. “Engaging customers with in-the-moment relevancy across digital channels has never been more important, and small improvements can drive big results. Airship Journeys brings breakthrough simplicity to the entire process and speeds insights-to-optimization to accelerate revenue growth.”
Recently, Airship was named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category (tied) and the second highest score in the Current Offering category.
About Airship
Thousands of the world’s leading brands rely on Airship to spark closer connections with their customers through highly contextual and relevant interactions. Only Airship’s Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, not which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.
With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005340/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom